ALRX stock: Zysolin Shows Promising Results in Animal Study

AlphaRx's specially-formulated Tobramycin nanoparticles increase survival rate in mice infected with Gram negative Pseudomonas Aeruginosa, suggesting Zysolin has potential in the treatment of Cystic Fibrosis and Gram-negative pneumonia.

MARKHAM, ON, June 3 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX nano stock) is pleased to announce pre-clinical data on Zysolin(TM), a Tobramycin compound encapsulated in the company's Nano Drug Delivery Platform intended for the treatment of Cystic Fibrosis and an adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients.

In the recent animal study, the therapeutic efficacy of Zysolin was investigated in a mouse model of Pseudomonas aeruginosa pneumonia. In this acute model, pneumonia developed rapidly, resulting in a high mortality rate, no mice survived after 24 hours of infection without treatment. Mice treated with Zysolin(TM) showed significantly better efficacy than Tobramycin, achieving 60% survival rate vs. 40% in the Tobramycin treatment group. An increase of survival by 50% or more, relative to vehicle control, indicates significant anti-microbial effect. The Tobramycin treatment group did not meet the study's end point.

Pseudomonas aeruginosa is a major cause of lung infections, particularly nosocomial pneumonia. Mortality rates of patients with P. aeruginosa pneumonia are higher than the mortality rates of patients with pneumonia caused by other pathogens because P. aeruginosa pneumonia frequently disseminates to cause bacteremia and sepsis. Currently, Gram-negative pneumonia carries a mortality risk as high as 50 percent in

AlphaRx Signs Cooperative Research and Development Agreement with US Army

MARKHAM, ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to report that AlphaRx and USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases) has entered into a Cooperative Research and Development Agreement for Material Transfer (MTA). The resulting joint R&D effort enables USAMRIID scientists to test the efficacy of AlphaRx's 'nanobiotics' for the treatment of severe intracellular bacterial infections caused by Category A pathogens in animal models. Category A pathogens are organisms classified by US Government used mainly in biological weapons that pose a risk to national security.

The MTA covers several 'nanobiotics' including Ciprofloxacin, Doxycycline and Gentamicin developed by AlphaRx. These are the usual antibiotics used to treat patients in a bioterrorism event. However, they all show limited efficacy clinically. AlphaRx believes that their specially-formulated version of these antibiotics provides improved intracellular activity in animal studies and may have better clinical efficacy.

AlphaRx is excited with the opportunity to work with the U.S. Army. It opens up a non-commercial application to AlphaRx's drug development programs, with the potential to be a provider to the national stockpile program, through Project Bioshield.

AlphaRx Provides Corporate and Development Update

MARKHAM, ON, May 20 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to provide shareholders with an update on recent corporate developments.

TSX Venture Exchange Application

--------------------------------

AlphaRx is seeking a listing with the TSX Venture Exchange. Research Capital Corporation is sponsoring the application. AlphaRx is in the process of raising up to $1,800,000 U.S. via a private placement in conjunction with the listing application. AlphaRx has been in correspondence with the TSX Venture Exchange and has responded to all comments raised to-date.

Corporate Website

-----------------

AlphaRx is working on a new and improved corporate website which will reflect all current business focus. This new website will be launched some time in June.

Product Development

-------------------

AlphaRx's current focus is on the development of 'nanobiotics' for the treatment of severe pneumonias. AlphaRx's high-priority development programs include Vansolin(TM) and Zysolin(TM).

Vansolin(TM), a specially-formulated Vancomycin nano-particulate formulation, is intended for the treatment of severe pneumonias caused by MRSA (Methicillin Resistant Staphylococcus Aureus) pathogens. Vansolin(TM) is undergoing pivotal animal studies. The Company will make a go/no go decision based on the outcome on these studies which will be available by mid-July.

Zysolin(TM), a specially-formulated Tobramycin nano-particulate formulation, intended for the treatment of severe pneumonias caused by gram negative pathogens such as Psedomonas Aeruginosa. The Company is developing Zysolin(TM) as a primary therapy for Cystic Fibrosis and an adjunctive therapy for ventilated patients with hospital-acquired, Gram-negative pneumonias. Zysolin(TM) is undergoing pivotal animal studies.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.

« Previous | All Messages | ALRX Message Board Home | Ignore Poster